Journal article
Antisense Therapy against CCR3 and the Common Beta Chain Attenuates Allergen-induced Eosinophilic Responses
Abstract
RATIONALE: The drug product TPI ASM8 contains two modified phosphorothioate antisense oligonucleotides designed to inhibit allergic inflammation by down-regulating human CCR3 and the common beta chain (beta(c)) of IL-3, IL-5, and granulocyte-macrophage colony-stimulating factor receptors.
OBJECTIVES: This study examined the effects of inhaled TPI ASM8 on sputum cellular influx, CCR3 and beta(c) mRNA and protein levels, and the airway …
Authors
Gauvreau GM; Boulet LP; Cockcroft DW; Baatjes A; Cote J; Deschesnes F; Davis B; Strinich T; Howie K; Duong M
Journal
American Journal of Respiratory and Critical Care Medicine, Vol. 177, No. 9, pp. 952–958
Publisher
American Thoracic Society
Publication Date
May 1, 2008
DOI
10.1164/rccm.200708-1251oc
ISSN
1073-449X
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Administration, InhalationAdultAllergensAsthmaCross-Over StudiesDouble-Blind MethodDrug CombinationsFemaleFlow CytometryFollow-Up StudiesForced Expiratory VolumeGene ExpressionHumansMaleMiddle AgedNebulizers and VaporizersOligonucleotides, AntisensePhosphorothioate OligonucleotidesPulmonary EosinophiliaRNA, MessengerReceptors, CCR3Receptors, CytokineReverse Transcriptase Polymerase Chain ReactionSputumTreatment Outcome